+ Filter
Loading...
DAG1
Anti-DAG1 Recombinant Antibody Products
- Anti-Human DAG1 Recombinant Antibody (DAG-6F4) (TAB-0738CLV)
-
Compare
- Anti-Human DAG1 Recombinant Antibody (DAG-3H9) (TAB-0739CLV)
-
Compare
- Anti-Human DAG1 Recombinant Antibody Fab Fragment (DAG-6F4) (TAB-0738CLV-F(E))
-
Compare
- Anti-Human DAG1 Recombinant Antibody Fab Fragment (DAG-3H9) (TAB-0739CLV-F(E))
-
Compare
- Anti-Human DAG1 Recombinant Antibody scFv Fragment (DAG-6F4) (TAB-0738CLV-S(P))
-
Compare
- Anti-Human DAG1 Recombinant Antibody scFv Fragment (DAG-3H9) (TAB-0739CLV-S(P))
-
Compare
More Infomation
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
This gene encodes dystroglycan, a central component of dystrophin-glycoprotein complex that links the extracellular matrix and the cytoskeleton in the skeletal muscle. The encoded preproprotein undergoes O- and N-glycosylation, and proteolytic processing to generate alpha and beta subunits. Certain mutations in this gene are known to cause distinct forms of muscular dystrophy. Alternative splicing results in multiple transcript variants, all encoding the same protein. [provided by RefSeq, Nov 2015]
Protein class
Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Transporters
Predicted location
Intracellular, Membrane (different isoforms)
Single cell type specificity
Cell type enhanced (Skeletal myocytes, Granulosa cells)
Immune cell specificity
Low immune cell specificity
Cell line specificity
Cell line enhanced (BEWO)
Interaction
Monomer. Heterodimer of alpha- and beta-dystroglycan subunits which are the central components of the dystrophin-glycoprotein complex. This complex then can form a dystrophin-associated glycoprotein complex (DGC) which is composed of three subcomplexes: a cytoplasmic complex comprised of DMD (or UTRN), DTNA and a number of syntrophins, such as SNTB1, SNTB2, SNTG1 and SNTG2, the transmembrane dystroglycan complex, and the sarcoglycan-sarcospan complex. Interacts (via the N-terminal of alphaDAG1) with LARGE1; the interaction enhances laminin binding (By similarity). Interacts with SGCD. Interacts with AGR2 and AGR3. Interacts (betaDAG1) with DMD; the interaction is inhibited by phosphorylation on the PPXY motif. Interacts (betaDAG1, via its PPXY motif) with UTRN (via its WWW and ZZ domains); the interaction is inhibited by phosphorylation on the PPXY motif. Interacts (betaDAG1, via its phosphorylated PPXY motif) with the SH2 domain-containing proteins, FYN, CSK, NCK and SHC. Interacts (betaDAG1) with CAV3 (via a central WW-like domain); the interaction disrupts the binding of DMD. BetaDAG1 directly interacts with ANK3, but not with ANK2; this interaction does not interfere with DMD-binding and is required for retention at costameres (By similarity). Identified in a dystroglycan complex that contains at least PRX, DRP2, UTRN, DMD and DAG1 (By similarity). Interacts with POMGNT1 (PubMed:27493216). (Microbial infection) Interacts with lassa virus and lymphocytic choriomeningitis virus glycoprotein (PubMed:16254364, PubMed:19324387). (Microbial infection) Interacts with surface molecules of mycobacterium leprae.
Molecular function
Host cell receptor for virus entry, Receptor
More Types Infomation
Related Signaling Pathways
BCR Signaling Pathway
cAMP Signaling Pathway
Related Diseases
Morphine Addiction
AGE-RAGE Signaling Pathway in Diabetic Complications